Abstract

Atopic dermatitis (AD) is a relatively common inflammatory skin disease identified by swollen, cracked or inflamed skin. Currently, the primary treatments for AD are corticosteroids. However, after prolonged usage, corticosteroids have the potential to produce severe side effects. Epigallocatechin gallate (EGCG), a compound found in tea, provides anti-inflammatory properties that offer a potential alternative to corticosteroids in treating AD. However, the delivery method of EGCG greatly affects its bioavailability. The skin’s barrier makes it hard to delivery EGCG directly through intact skin. Nanoparticles provide an intriguing option for atopic transdermal delivery of EGCG due to their biochemical properties and ease of application. In this study, biodegradable self-assembling gelatin/EGCG nanoparticles (GE NPs) were synthesized for AD treatment. GE NPs had a spherical morphology with an average diameter of 112 nm and a zeta potential of nearly 23 mV. Cell viability assays indicated 10 μg/mL concentrations of EGCG or GE were non-toxic to human dermal fibroblast (WS1) cells. Intracellular quantification of dye conjugated GE was proceeded, and it revealed high amounts of fluorescence dye in cells. Lipopolysaccharide-inflamed WS1 cells were treated with EGCG solution or GE NPs, and IL-6 and IL-8 cytokine expression was assessed by ELISA method. GE NPs decreased inflammation as demonstrated by reducing IL-6 and IL-8 expression in WS1 cells in vitro with EGCG concentrations as low as 1 μg/mL. The topical delivery of GE NPs in vivo was examined by dropping different formulations on nude mice skin. GE NPs demonstrate greater skin absorbance than free EGCG in vivo and without eliciting adverse effects. This approach provides a novel alternative potential treatment for skin inflammatory diseases.

Original languageEnglish
Article number188
JournalJournal of Polymer Research
Volume24
Issue number11
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Gelatin
Drug delivery
Self assembly
Skin
Nanoparticles
Adrenal Cortex Hormones
Dyes
Interleukin-8
Interleukin-6
Coloring Agents
Zeta potential
Fibroblasts
epigallocatechin gallate
Assays
Fluorescence
Cells
Lipopolysaccharides
Anti-Inflammatory Agents
Atopic Dermatitis
Cytokines

Keywords

  • Anti-inflammation
  • Atopic dermatitis
  • EGCG
  • Gelatin nanoparticles
  • Skin
  • Trans-dermal drug delivery system

ASJC Scopus subject areas

  • Polymers and Plastics
  • Organic Chemistry
  • Materials Chemistry

Cite this

Preparation of gelatin/epigallocatechin gallate self-assembly nanoparticles for transdermal drug delivery. / Drew, Victor J.; Huang, Hsin Yi; Tsai, Zheng Han; Tsai, Hsiou Hsin; Tseng, Ching Li.

In: Journal of Polymer Research, Vol. 24, No. 11, 188, 01.10.2017.

Research output: Contribution to journalArticle

@article{307d7f367f84412ba70d35224e82cfb3,
title = "Preparation of gelatin/epigallocatechin gallate self-assembly nanoparticles for transdermal drug delivery",
abstract = "Atopic dermatitis (AD) is a relatively common inflammatory skin disease identified by swollen, cracked or inflamed skin. Currently, the primary treatments for AD are corticosteroids. However, after prolonged usage, corticosteroids have the potential to produce severe side effects. Epigallocatechin gallate (EGCG), a compound found in tea, provides anti-inflammatory properties that offer a potential alternative to corticosteroids in treating AD. However, the delivery method of EGCG greatly affects its bioavailability. The skin’s barrier makes it hard to delivery EGCG directly through intact skin. Nanoparticles provide an intriguing option for atopic transdermal delivery of EGCG due to their biochemical properties and ease of application. In this study, biodegradable self-assembling gelatin/EGCG nanoparticles (GE NPs) were synthesized for AD treatment. GE NPs had a spherical morphology with an average diameter of 112 nm and a zeta potential of nearly 23 mV. Cell viability assays indicated 10 μg/mL concentrations of EGCG or GE were non-toxic to human dermal fibroblast (WS1) cells. Intracellular quantification of dye conjugated GE was proceeded, and it revealed high amounts of fluorescence dye in cells. Lipopolysaccharide-inflamed WS1 cells were treated with EGCG solution or GE NPs, and IL-6 and IL-8 cytokine expression was assessed by ELISA method. GE NPs decreased inflammation as demonstrated by reducing IL-6 and IL-8 expression in WS1 cells in vitro with EGCG concentrations as low as 1 μg/mL. The topical delivery of GE NPs in vivo was examined by dropping different formulations on nude mice skin. GE NPs demonstrate greater skin absorbance than free EGCG in vivo and without eliciting adverse effects. This approach provides a novel alternative potential treatment for skin inflammatory diseases.",
keywords = "Anti-inflammation, Atopic dermatitis, EGCG, Gelatin nanoparticles, Skin, Trans-dermal drug delivery system",
author = "Drew, {Victor J.} and Huang, {Hsin Yi} and Tsai, {Zheng Han} and Tsai, {Hsiou Hsin} and Tseng, {Ching Li}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s10965-017-1342-0",
language = "English",
volume = "24",
journal = "Journal of Polymer Research",
issn = "1022-9760",
publisher = "Springer Netherlands",
number = "11",

}

TY - JOUR

T1 - Preparation of gelatin/epigallocatechin gallate self-assembly nanoparticles for transdermal drug delivery

AU - Drew, Victor J.

AU - Huang, Hsin Yi

AU - Tsai, Zheng Han

AU - Tsai, Hsiou Hsin

AU - Tseng, Ching Li

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Atopic dermatitis (AD) is a relatively common inflammatory skin disease identified by swollen, cracked or inflamed skin. Currently, the primary treatments for AD are corticosteroids. However, after prolonged usage, corticosteroids have the potential to produce severe side effects. Epigallocatechin gallate (EGCG), a compound found in tea, provides anti-inflammatory properties that offer a potential alternative to corticosteroids in treating AD. However, the delivery method of EGCG greatly affects its bioavailability. The skin’s barrier makes it hard to delivery EGCG directly through intact skin. Nanoparticles provide an intriguing option for atopic transdermal delivery of EGCG due to their biochemical properties and ease of application. In this study, biodegradable self-assembling gelatin/EGCG nanoparticles (GE NPs) were synthesized for AD treatment. GE NPs had a spherical morphology with an average diameter of 112 nm and a zeta potential of nearly 23 mV. Cell viability assays indicated 10 μg/mL concentrations of EGCG or GE were non-toxic to human dermal fibroblast (WS1) cells. Intracellular quantification of dye conjugated GE was proceeded, and it revealed high amounts of fluorescence dye in cells. Lipopolysaccharide-inflamed WS1 cells were treated with EGCG solution or GE NPs, and IL-6 and IL-8 cytokine expression was assessed by ELISA method. GE NPs decreased inflammation as demonstrated by reducing IL-6 and IL-8 expression in WS1 cells in vitro with EGCG concentrations as low as 1 μg/mL. The topical delivery of GE NPs in vivo was examined by dropping different formulations on nude mice skin. GE NPs demonstrate greater skin absorbance than free EGCG in vivo and without eliciting adverse effects. This approach provides a novel alternative potential treatment for skin inflammatory diseases.

AB - Atopic dermatitis (AD) is a relatively common inflammatory skin disease identified by swollen, cracked or inflamed skin. Currently, the primary treatments for AD are corticosteroids. However, after prolonged usage, corticosteroids have the potential to produce severe side effects. Epigallocatechin gallate (EGCG), a compound found in tea, provides anti-inflammatory properties that offer a potential alternative to corticosteroids in treating AD. However, the delivery method of EGCG greatly affects its bioavailability. The skin’s barrier makes it hard to delivery EGCG directly through intact skin. Nanoparticles provide an intriguing option for atopic transdermal delivery of EGCG due to their biochemical properties and ease of application. In this study, biodegradable self-assembling gelatin/EGCG nanoparticles (GE NPs) were synthesized for AD treatment. GE NPs had a spherical morphology with an average diameter of 112 nm and a zeta potential of nearly 23 mV. Cell viability assays indicated 10 μg/mL concentrations of EGCG or GE were non-toxic to human dermal fibroblast (WS1) cells. Intracellular quantification of dye conjugated GE was proceeded, and it revealed high amounts of fluorescence dye in cells. Lipopolysaccharide-inflamed WS1 cells were treated with EGCG solution or GE NPs, and IL-6 and IL-8 cytokine expression was assessed by ELISA method. GE NPs decreased inflammation as demonstrated by reducing IL-6 and IL-8 expression in WS1 cells in vitro with EGCG concentrations as low as 1 μg/mL. The topical delivery of GE NPs in vivo was examined by dropping different formulations on nude mice skin. GE NPs demonstrate greater skin absorbance than free EGCG in vivo and without eliciting adverse effects. This approach provides a novel alternative potential treatment for skin inflammatory diseases.

KW - Anti-inflammation

KW - Atopic dermatitis

KW - EGCG

KW - Gelatin nanoparticles

KW - Skin

KW - Trans-dermal drug delivery system

UR - http://www.scopus.com/inward/record.url?scp=85031904771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031904771&partnerID=8YFLogxK

U2 - 10.1007/s10965-017-1342-0

DO - 10.1007/s10965-017-1342-0

M3 - Article

VL - 24

JO - Journal of Polymer Research

JF - Journal of Polymer Research

SN - 1022-9760

IS - 11

M1 - 188

ER -